Uray Iván Péter

Name: Uray Iván Péter

Affiliation:

Debreceni Egyetem. Általános Orvostudományi Kar. Onkológiai Intézet / University of Debrecen. Faculty of Medicine. Department of Clinical Oncology

Other profiles: MTMT

Degree:

MD, Debreceni Orvostudományi Egyetem (1994)
PhD, Debreceni Egyetem (2001)
Habilitáció, Debreceni Egyetem (2019)

Publication list

Tudóstér co-authors statistics filterable publication list

Export to RIS (EndNote, Mendeley, RefWorks, Zotero etc.)

Upload publications

Request certified publication list

Uploaded publications:

Publications in DEA:

OA:

Date range:

1995-2025

2025

Lengyel, M., Molnár, Á., Nagy, T., Jdeed, S., Garai, I., Horváth, Z., Uray, I. P.: Zymogen granule protein 16B (ZG16B) is a druggable epigenetic target to modulate the mammary extracellular matrix.
Cancer Sci. 116 (1), 81-94, 2025.

doi DEA WoS Scopus

Journal metrics:

Q2 Cancer Research (2024)

D1 Medicine (miscellaneous) (2024)

Q1 Oncology (2024)

2023

Jambrovics, K., Póliska, S., Scholtz, B., Uray, I. P., Balajthy, Z.: ATO Increases ROS Production and Apoptosis of Cells by Enhancing Calpain-Mediated Degradation of the Cancer Survival Protein TG2.
Int. J. Mol. Sci. 24 (13), 1-11, (article identifier: 10938), 2023.

doi DEA WoS Scopus

Journal metrics:

Q2 Catalysis

Q1 Computer Science Applications

D1 Inorganic Chemistry

Q1 Medicine (miscellaneous)

Q2 Molecular Biology

D1 Organic Chemistry

Q1 Physical and Theoretical Chemistry

D1 Spectroscopy

Kola, J. B., Turarova, B., Csige, D., Sipos, Á., Varga, L., Gergely, B., Refai, F. A., Uray, I. P., Docsa, T., Uray, K.: Stretch-Induced Down-Regulation of HCN2 Suppresses Contractile Activity.
Molecules. 28 (11), 1-14, (article identifier: 4359), 2023.

doi DEA WoS Scopus

Journal metrics:

Q1 Analytical Chemistry

Q1 Chemistry (miscellaneous)

Q2 Drug Discovery

Q2 Medicine (miscellaneous)

Q3 Molecular Medicine

Q2 Organic Chemistry

Q1 Pharmaceutical Science

Q2 Physical and Theoretical Chemistry

Jambrovics, K., Botó, P., Pap, A., Sarang, Z., Kolostyák, Z., Czimmerer, Z., Szatmári, I., Fésüs, L., Uray, I. P., Balajthy, Z.: Transglutaminase 2 associated with PI3K and PTEN in a membrane-bound signalosome platform blunts cell death.
Cell Death Dis. 14 (3), 1-10, (article identifier: 217), 2023.

doi DEA WoS Scopus

Journal metrics:

Q1 Cancer Research

Q1 Cell Biology

Q1 Cellular and Molecular Neuroscience

Q1 Immunology

D1 Medicine (miscellaneous)

2022

Jdeed, S., Lengyel, M., Uray, I. P.: Redistribution of the SWI/SNF Complex Dictates Coordinated Transcriptional Control over Epithelial-Mesenchymal Transition of Normal Breast Cells through TGF-[béta] Signaling.
Cells. 11 (17), 1-15, (article identifier: 2633), 2022.

doi DEA WoS Scopus

Journal metrics:

Q1 Biochemistry, Genetics and Molecular Biology (miscellaneous)

Jdeed, S., Erdős, E., Bálint, B. L., Uray, I. P.: The Role of ARID1A in the Nonestrogenic Modulation of IGF-1 Signaling.
Mol. Cancer Res. 20 (7), 1071-1082, 2022.

doi DEA WoS Scopus

Journal metrics:

Q1 Cancer Research

Q1 Molecular Biology

Q1 Oncology

2021

Uray, I. P., Uray, K.: Mechanotransduction at the Plasma Membrane-Cytoskeleton Interface.
Int. J. Mol. Sci. 22 (21), 1-23, 2021.

doi DEA WoS Scopus

Journal metrics:

Q2 Catalysis

Q1 Computer Science Applications

Q1 Inorganic Chemistry

Q1 Medicine (miscellaneous)

Q2 Molecular Biology

Q1 Organic Chemistry

Q1 Physical and Theoretical Chemistry

D1 Spectroscopy

2020

Szivos, L., Virga, J., Hortobágyi, T., Zahuczky, G., Uray, I. P., Jenei, A., Bognár, L., Árkosy, P., Klekner, Á.: Az inváziós spektrum prognosztikai jelentősége glioblastomában.
Ideggyogy. Szle. 73 (9-10), 317-325, 2020.

doi DEA WoS Scopus

Journal metrics:

Q4 Neurology

Q4 Neurology (clinical)

Jambrovics, K., Uray, I. P., Keillor, J. W., Fésüs, L., Balajthy, Z.: Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2.
Cancers (Basel). 12 (3), 648-, 2020.

doi DEA WoS Scopus

Journal metrics:

Q2 Cancer Research

Q1 Oncology

2019

10.

Kocsis, J., Szekanecz, É., Bassam, A., Uhlyarik, A., Pápai, Z., Rubovszky, G., Mezősi, E., Rucz, K., Garai, I., Nagy, E. V., Uray, I. P., Horváth, Z.: First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer: efficacy and Safety Analysis.
Exp. Clin. Endocrinol. Diabetes. 127 (4), 240-246, 2019.

doi DEA

Journal metrics:

Q3 Endocrinology

Q3 Endocrinology, Diabetes and Metabolism

Q2 Internal Medicine

Q2 Medicine (miscellaneous)

11.

Jambrovics, K., Uray, I. P., Keresztessy, Z., Keillor, J. W., Fésüs, L., Balajthy, Z.: Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-kB activation.
Haematol-Hematol. J. 104 (3), 505-515, 2019.

doi DEA WoS Scopus

Journal metrics:

D1 Hematology

2018

12.

Chowdhury, P., Powell, R. T., Stephan, C., Uray, I. P., Talley, T., Karki, M., Tripathi, D. N., Park, Y. S., Mancini, M. A., Davies, P. J. A., Dere, R.: Bexarotene: a Novel Modulator of AURKA and the Primary Cilium in VHL-deficient Cells.
J. Cell Sci. 131, 1-12, 2018.

doi DEA

Journal metrics:

Q1 Cell Biology

2017

13.

Zhang, L., Shen, J., Yin, Y., Peng, Y., Wang, L., Hsieh, H. J., Shen, Q., Brown, P. H., Tao, K., Uray, I. P., Peng, G.: Identifying cell cycle modulators that selectively target aridia deficiency using high-throughput image-based screening.
SLAS Discovery. 1 (1), 1-14, 2017.

DEA

14.

Zhang, L., Peng, Y., Uray, I. P., Shen, J., Wang, L., Peng, X., Brown, P. H., Tu, W., Peng, G.: Natural product [béta]-thujaplicin inhibits homologous recombination repair and sensitizes cancer cells to radiation therapy.
DNA Repair. 60, 89-101, 2017.

doi DEA

Journal metrics:

D1 Biochemistry

Q1 Cell Biology

Q1 Molecular Biology

2016

15.

Uray, I. P., Dmitrovsky, E., Brown, P. H.: Retinoids and Rexinoids in Cancer Prevention: From Laboratory to Clinic.
Semin. Oncol. 43 (1), 49-64, 2016.

doi DEA

Journal metrics:

Q1 Hematology

Q1 Oncology

16.

Shepherd, J. H., Uray, I. P., Mazumdar, A., Tsimelzon, A., Savage, M., Hilsenbeck, S. G., Brown, P. H.: The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression.
Oncotarget. 7 (11), 1-16, 2016.

doi DEA

Journal metrics:

Q1 Oncology

2015

17.

Uray, I. P., Rodenberg, J. M., Zhang, Y., Hill, J. L., Brown, P. H.: Abstract 2804: The thiazolidinedione pioglitazone enhances the cancer preventive activity of the rexinoid LG100268 in Her2/neu induced breast cancer.
Cancer Res. 75 (15), 2804, 2015.

doi DEA

18.

Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I. M., Uray, I. P., Wu, X., Brown, P. H., Shen, X., Mills, G. B., Peng, G.: ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
Cancer Discov. 5 (7), 752-767, 2015.

doi DEA

Journal metrics:

D1 Oncology

2014

19.

Batra, N., Speers, C., Uray, I. P., Mazumdar, A., Tsimelzon, A., Hilsenbeck, S. G., Mills, G. B., Brown, P. H.: Abstract 3299: Maternal embryonic leucine zipper kinase is critical for the growth and migration of triple negative breast cancer cells.
Cancer Res. 74 (19), 3299-3299, 2014.

doi DEA

20.

Xiong, A., Chen, H., Yang, Z., Cai, G., Wang, L., Ding, C., Xu, G. G., Wild, C., Ye, N., Uray, I. P., Zhou, J., Shen, Q.: Abstract 3805: Anticancer agent HJC0416 inhibits the growth of breast cancer xenografts via downregulating STAT3 signaling.
Cancer Res. 74 (19), 3805-3805, 2014.

doi DEA

21.

Sárvári, A. K., Veréb, Z., Uray, I. P., Fésüs, L., Balajthy, Z.: Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro.
Biochem. Biophys. Res. Commun. 450 (4), 1383-1389, 2014.

doi DEA

Journal metrics:

Q2 Biochemistry

Q1 Biophysics

Q3 Cell Biology

Q2 Molecular Biology

2012

22.

Hartman, Z. C., Tsimelzon, A., Uray, I. P., Hill, J. L., Zhang, Y., Mazumdar, A., Hilsenbeck, S. G., Chang, J., Mills, G. B., Brown, P. H.: Abstract 4862: Autocrine secreted IL-6 and IL-8 play critical and non-redundant roles in basal-like breast cancer cell transformation and growth in vitro and in vivo.
Cancer Res. 72 (8), 4862-4862, 2012.

doi DEA

23.

Wang, C., Uray, I. P., Mazumdar, A., Mayer, J. A., Brown, P. H.: SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE).
Breast Cancer Res. Treat. 134 (1), 101-115, 2012.

doi DEA

Journal metrics:

Q1 Cancer Research

Q1 Oncology

2011

24.

Uray, I. P., Rodenberg, J. M., Bissonnette, R. P., Brown, P. H., Mancini, M. A.: Cancer-Preventive Rexinoid Modulates Neutral Lipid Contents of Mammary Epithelial Cells through a Peroxisome Proliferator-Activated Receptor [gamma]-Dependent Mechanism.
Molecular Pharmacology. 81 (2), 228-238, 2011.

doi DEA

Journal metrics:

D1 Molecular Medicine

D1 Pharmacology

25.

Uray, I. P., Brown, P. H.: Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.
Recent Results Cancer Res. 188, 147-162, 2011.

doi DEA

Journal metrics:

Q3 Cancer Research

Q1 Medicine (miscellaneous)

Q2 Oncology